JUUL Statement: FDA Has Revoked Its Sales Refusal Order, And Some Products Will Continue To Be Sold During The Review Period

JUUL statement: FDA has revoked its sales refusal order, and some products will continue to be sold during the review period

JUUL announced that the FDA has revoked its June 2022 marketing denial order (MDOs) for JUUL products and re-included JUUL's application in the scientific review process.

[Two Supreme News] On June 6, local time, the US e-cigarette brand JUUL issued a statement announcing that the US Food and Drug Administration (FDA) has revoked its June 2022 marketing denial order (MDOs) for JUUL products and re-included JUUL's application in the scientific review process. (See report: US FDA revokes 2022 sales denial order for JUUL and restarts review process)

JUUL expressed the following views in the statement:

1. JUUL appreciates the FDA's decision and looks forward to re-establishing contact with the agency to strive for market approval of JUUL products through a science-based and evidence-based process.

2. JUUL is confident in the quality and substance of its application and believes that after a comprehensive review of science and evidence, it will be proven that JUUL's products meet the statutory safety standards for protecting public health.

3. During this review period, JUUL devices and 5.0% and 3.0% nicotine strength Virginia tobacco and mint JUUL cartridges will continue to be available on the market.